As the public’s interest in COVID-19 products continues to wane and the autoimmune medicine Humira settles into life without exclusivity, the anti-cancer agent Keytruda is set to rule the drug marketplace for years to come.
Tag Archive for: Eli Lilly
It’s summer 2023. By now, many of us have “emerged”, as they say. We are getting out and about and making up for the lost time of the past three years. And much of this progress is thanks to the COVID-19 vaccines and treatments from Pfizer, BioNTech, and Moderna, which played a major role in helping us put the pandemic in the rearview mirror.
Nektar Therapeutics accused Eli Lilly of scheming to ensure rezpegaldesleukin would not succeed after acquiring a competing medicine.
The company is leaning on Mounjaro, approved last May in the U.S. for diabetes, to soften the hit from insulin price cuts and competition for cancer therapy Alimta.
The results are based, on average, across two late-stage studies after intensive lifestyle changes or with continued treatment, before patients stopped taking the drug.
The findings underscore that “earlier detection and diagnosis can really change the trajectory of this disease,” said Anne White, president of neuroscience at Lilly.
The 2023 Alzheimer’s Association International Conference will feature further analyses of the recent traditionally approved Leqembi and a highly anticipated update on Eli Lilly’s donanemab.
Americans without health insurance pay an average of $98 for Eli Lilly’s generic insulin despite the company’s May 1 pledge to cut its list price to $25 per vial, according to a survey of more than 300 U.S. pharmacies by U.S. Senator Elizabeth Warren’s office released on Thursday.
The two companies have been partners since 2018, when Lilly paid Sigilon $63 million for a licensing deal to develop cell therapies targeting type 1 diabetes and made an undisclosed equity investment.
Eli Lilly has agreed to pay $2.4 million to the U.S. Equal Employment Opportunity Commission to settle a lawsuit the agency filed, claiming that the pharma giant discriminated against older job candidates by changing its hiring preferences in 2017 to recruit more millennials.
